GLP-1 & Incretin Science
Why Weight Loss Can Restore Ovulation
Obesity and insulin resistance disrupt ovulatory function, and polycystic ovary syndrome is the clearest case. Reducing weight and improving insulin sensitivity can restore ovulation. Salamun and colleagues reported liraglutide increasing IVF pregnancy rates in obese PCOS women with poor response to first-line treatment.
Key facts
- Mechanism
- Improved insulin sensitivity, weight reduction
- Population most affected
- PCOS
- Pilot randomised study
- Salamun 2018 (PMID 29703793)
- Journal
- Eur J Endocrinol, July 2018
- Compound studied
- Liraglutide
- Setting
- IVF, poor response to first-line treatment
Why insulin resistance disrupts ovulation
High circulating insulin acts on the ovary and alters steroid production, raising androgen output and disturbing the hormonal sequence that drives follicle maturation and release. It also lowers sex hormone-binding globulin, which raises free androgen further. The result is disrupted ovulatory cycling, and it is a hormonal consequence of the metabolic state rather than a primary ovarian defect.
Why PCOS is the clearest case
Polycystic ovary syndrome couples reproductive and metabolic disturbance in the same condition — irregular or absent ovulation alongside insulin resistance in a large proportion of those affected. That coupling is why an intervention acting on the metabolic side can change the reproductive side, and why this population appears repeatedly in the literature.
Research material referenced
Retatrutide 10mg — third-party HPLC tested
What the 2018 study examined
Salamun and colleagues published a pilot randomised study in the European Journal of Endocrinology examining liraglutide and IVF pregnancy rates in obese women with PCOS who had responded poorly to first-line reproductive treatment. A pilot randomised study is early-stage evidence in a defined and difficult population, not a general statement about fertility.
Why the effect is not attributable to the drug alone
The same attribution problem that runs through this entire class. Weight loss itself improves ovulatory function and has done so long before these compounds existed, through diet and surgery. Whether an incretin does anything beyond causing the weight loss is a separate question, and one this design cannot separate.
Why this matters even to people not seeking pregnancy
Because a return of ovulation is a return of fertility whether or not it was wanted. Someone whose cycles were irregular or absent may have been relying on that as a practical matter. Restoring ovulation changes that circumstance without any announcement, which is the substance of the convergence described in the companion article on this site.
What this concerns
Licensed medicines studied in registered trials under clinical supervision. Nothing supplied on this site is a GLP-1 receptor agonist, affects fertility, or has any place in reproductive care. These findings describe medicines, and decisions about fertility belong with a clinician.
Extended research context
The GLP-1 & Incretin Science deep dive
Deep dive: the two routes to a bigger effect
Every compound trying to beat GLP-1 alone has taken one of two routes. The first adds more receptors from the same hormone family — GIP in tirzepatide, GIP and glucagon in retatrutide. The second adds a non-incretin satiety hormone, which in practice means amylin: CagriSema combines cagrilintide with semaglutide, and amycretin engages both receptors from one molecule. Both routes work, because they recruit signalling pathways that do not fully overlap. Neither has escaped the constraint that binds all of them, which is that gastrointestinal tolerability worsens as effect size grows.
Deep dive: why a percentage is not a result
The most-quoted numbers in this field are the least comparable. REDEFINE 1 reported 22.7% and 20.4% for the same compound in the same trial — the first among participants who adhered to treatment, the second across everyone randomised. TRIUMPH-1 reported 28.3% in an uncomplicated obesity population while TRIUMPH-3 reported up to 22.6% in adults with established cardiovascular disease, using the same compound. Before any two figures can be compared they have to match on estimand, population, duration, comparator and whether the number is placebo-adjusted. Most published comparisons match on none of them.
Deep dive: what happens after the trial stops
Every headline figure describes weight while treatment continues. The STEP-1 extension found that a year after semaglutide was stopped, participants had given back roughly two-thirds of what they lost, moving from 17.3% mean reduction to a net 5.6% — though average weight remained below baseline and nearly half stayed at least 5% down. Meta-analysis puts regain at around 0.8 kg per month. This is why maintenance studies such as TRIUMPH-6 matter more to the field's future than another two points of peak reduction.
Research applications
- ▸Comparing incretin and amylin compounds on a like-for-like basis
- ▸Interpreting estimands, thresholds and placebo-adjusted figures in trial reports
- ▸Tracking the obesity pipeline across sponsors and jurisdictions
- ▸Understanding receptor pharmacology behind GLP-1, GIP, glucagon and amylin
- ▸Distinguishing licensed medicines from investigational compounds
Handling checklist
- ✓Identify which estimand a quoted percentage comes from before citing it
- ✓Check the trial population and baseline BMI against the comparison you are making
- ✓Confirm the duration and whether the reduction curve had plateaued
- ✓Read discontinuation rates alongside efficacy figures
- ✓Verify every NCT identifier against ClinicalTrials.gov rather than secondary reporting
Common research-handling mistakes
Learnt from thousands of researcher orders across our UK labs.
✗ Comparing headline percentages across different trials
Fix: Population, duration, estimand and comparator all differ; the numbers are not interchangeable.
✗ Quoting the larger of two figures from the same trial
Fix: Name the estimand. Efficacy and treatment-policy answer different questions.
✗ Treating peak reduction as a durable outcome
Fix: Substantial regain follows cessation across the class; peak figures describe a maintained state.
✗ Assuming an oral route means a weaker mechanism
Fix: Route and receptor count are independent. Orforglipron is weaker because it hits one receptor, not because it is a tablet.
✗ Reading investigational compounds as available treatments
Fix: Most of this pipeline holds no authorisation anywhere; mazdutide is approved only in China.
Continue researching
Peer-reviewed guides, comparators and matched reference materials.
Related questions researchers ask
- Which weight-loss compound produces the largest reduction?
- What is the difference between CagriSema and amycretin?
- What is an amylin receptor agonist?
- How much weight is regained after stopping a GLP-1?
- Why does CagriSema report two different percentages?
- Why is orforglipron less effective than retatrutide?
Frequently asked questions
- Why does insulin resistance affect ovulation?
- High insulin alters ovarian steroid production and lowers sex hormone-binding globulin, raising free androgen and disturbing follicle maturation.
- What did the 2018 study find?
- It was a pilot randomised study of liraglutide and IVF pregnancy rates in obese PCOS women with poor response to first-line treatment — early-stage evidence in a specific population.
- Is the effect from the drug or the weight loss?
- Not separable. Weight loss alone improves ovulatory function, and the two occur together in the same participants.
Primary sources & clinical trials
Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.
- PubMedSalamun V et al., Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study — Eur J Endocrinol 2018 (PMID 29703793)pubmed.ncbi.nlm.nih.gov
- PubMedSaad Alfaiz A et al., GLP-1 receptor agonists and preconception planning — Ann Med Surg 2025 (PMID 41377305)pubmed.ncbi.nlm.nih.gov
- PubMedHviid KVR et al., Periconceptional GLP-1 receptor agonist exposure and obstetric outcomes — Hum Reprod Open 2026 (PMID 41852577)pubmed.ncbi.nlm.nih.gov
- TrialClinicalTrials.gov · TRIUMPH-1 (NCT05929066) — Retatrutide pivotal obesity trialclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-6 (NCT06859268) — Maintenance of weight reductionclinicaltrials.gov
- RefNovo Nordisk · CagriSema REDEFINE 1, published in NEJMprnewswire.com
- PubMedAmycretin phase 1b/2a subcutaneous study — PubMed (PMID 40550231)pubmed.ncbi.nlm.nih.gov
- RefTrajectory of weight regain after GLP-1 cessation — eClinicalMedicinethelancet.com
- PubMedOrforglipron: A Comprehensive Review — Int J Mol Sci 2026 (PMID 41683830)pubmed.ncbi.nlm.nih.gov
- EMAICH E9(R1) — estimands in clinical trials (EMA)ema.europa.eu
- GuidelineGoogle — Creating helpful, reliable, people-first contentdevelopers.google.com
Written and reviewed by
Jack Muncaster · Founder, UK Peptides
Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.
More GLP-1 & Incretin Science articles
- Restored Fertility and Reduced Contraceptive AbsorptionOne effect makes conception more likely; another can reduce contraceptive protection. They act in the same population, and neither announces itself.
- When the Reason for Treatment Causes the OutcomePeople given a drug differ from those not given it — by the condition that prompted it. A 2026 Danish cohort shows the problem unusually clearly.
- Why Age Changes the CalculationThe same weight reduction carries different consequences at 75 than at 45. Lean mass, bone and nutritional intake all sit differently.
- Where a Peptide Stops Being a DrugFDA treats 40 residues or fewer as a peptide — a drug. Longer is a protein, a biologic. That single number governs how generics reach the market.
- When the Intended Effect Goes Too FarA 2026 systematic review describes gastroparesis as an under-recognised complication. It is the drug's own mechanism crossing into pathology.
Popular across the research hub
One flagship guide from every other research category — keep exploring.
- Retatrutide ResearchWhat Is a Triple Agonist?
- GHK-Cu (Copper Peptide)GHK-Cu and Collagen Synthesis Research
- TB-500 (Thymosin β4 fragment)How Thymosin Beta-4 Was Discovered
- BPC-157 (Pentadecapeptide)The Proline Problem in BPC-157 Synthesis
- CJC-1295 & IpamorelinIpamorelin Molecular Weight and Physical Properties
- Peptide ReferenceAspartimide Formation and Why It Hides
- Bacteriostatic WaterBacteriostatic Water vs Bacteriostatic Sodium Chloride
- Research & Regulatory NewsThe Compounded GLP-1 Crackdown
- MOTS-c (Mitochondrial Peptide)MOTS-c and Exercise: What the Published Research Shows
- Semax (ACTH Fragment Peptide)Semax in the Published Literature
- Selank (Tuftsin Analogue)Selank Structure, Sequence and Physical Properties
- DSIP (Delta Sleep-Inducing Peptide)The Barrier Any Central Claim Has to Cross
- KLOW (Blend)Storing Four Peptides Under One Set of Conditions
- GLOW (Blend)Storing a Blend: The Weakest Component Governs
- MT-2 (Melanotan II)The Receptor a Non-Selective Agonist Also Reaches
- IGF-1 LR3Eighty-Three Residues, and What That Changes
- GlutathioneKidney and Intestine, and Why Position Matters
- NAD+Separate Pools in Separate Compartments
- KPVWhat the Colitis Models Reported